PRF Technologies Ltd. (PRFX) Research

PRF Technologies Ltd. operates as a specialized pharmaceutical company, currently in the clinical development stage, with a focus on pioneering treatments that deliver sustained post-surgical pain management. Central to its pipeline is PRF-110, a distinctive clear, viscous, oil-based solution. This innovative product is engineered for direct application into surgical incisions, aiming to provide targeted and prolonged alleviation of discomfort following operations. PRF-110 is presently undergoing assessment in two pivotal Phase 3 clinical trials, specifically for individuals recovering from bunionectomy and hernia repair procedures. The company, which was originally incorporated in 2007 under the name PainReform Ltd., maintains its headquarters in Tel Aviv, Israel.

Market snapshot

Symbol
PRFX
Price
$1.65
Day change
-10.81%
Market cap
$132.9K
P/E ratio
-0.04x
52-week range
1.28-17.95
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic

Recent news

  • Why Is PRF Tech Stock Falling On Monday?

    PRF Technologies (NASDAQ: PRFX) stock falls sharply Monday morning. Read why analysts see this as a market correction after Friday's 186% surge.

Peer companies

  • Avenue Therapeutics, Inc. (ATXI)
  • Dermata Therapeutics, Inc. (DRMA)
  • PMGC Holdings Inc. (ELAB)
  • NewcelX Ltd. (NCEL)
  • NKGen Biotech, Inc. Common Stock (NKGN)
  • Psyence Biomedical Ltd. (PBM)
  • Universe Pharmaceuticals Inc. (UPC)
  • Virax Biolabs Group Limited (VRAX)

Recent insider activity

  • Aviel Sigal — trade (43 shares) on 2026-03-18
  • Aviel Sigal — trade (104 shares) on 2026-03-18
  • Aviel Sigal — trade (612 shares) on 2026-03-18
  • Aviel Sigal — trade (3000 shares) on 2026-03-18
  • BARON ELLEN S — trade (50 shares) on 2026-03-18

Open PRF Technologies Ltd. (PRFX) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.